These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 25542094)

  • 1. New pathogenic and therapeutic paradigms in atopic dermatitis.
    Malajian D; Guttman-Yassky E
    Cytokine; 2015 Jun; 73(2):311-8. PubMed ID: 25542094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic therapies in atopic dermatitis: The pipeline.
    Renert-Yuval Y; Guttman-Yassky E
    Clin Dermatol; 2017; 35(4):387-397. PubMed ID: 28709570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The translational revolution and use of biologics in patients with inflammatory skin diseases.
    Noda S; Krueger JG; Guttman-Yassky E
    J Allergy Clin Immunol; 2015 Feb; 135(2):324-36. PubMed ID: 25541257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.
    Brunner PM; Guttman-Yassky E; Leung DY
    J Allergy Clin Immunol; 2017 Apr; 139(4S):S65-S76. PubMed ID: 28390479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?
    Guttman-Yassky E; Krueger JG
    Curr Opin Immunol; 2017 Oct; 48():68-73. PubMed ID: 28869867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications.
    Czarnowicki T; Krueger JG; Guttman-Yassky E
    J Allergy Clin Immunol Pract; 2014; 2(4):371-9; quiz 380-1. PubMed ID: 25017523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
    D'Erme AM; Romanelli M; Chiricozzi A
    Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin.
    Correa da Rosa J; Malajian D; Shemer A; Rozenblit M; Dhingra N; Czarnowicki T; Khattri S; Ungar B; Finney R; Xu H; Zheng X; Estrada YD; Peng X; Suárez-Fariñas M; Krueger JG; Guttman-Yassky E
    J Allergy Clin Immunol; 2015 Mar; 135(3):712-20. PubMed ID: 25583101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
    Hamilton JD; Suárez-Fariñas M; Dhingra N; Cardinale I; Li X; Kostic A; Ming JE; Radin AR; Krueger JG; Graham N; Yancopoulos GD; Pirozzi G; Guttman-Yassky E
    J Allergy Clin Immunol; 2014 Dec; 134(6):1293-1300. PubMed ID: 25482871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines.
    Boguniewicz M
    J Allergy Clin Immunol Pract; 2017; 5(6):1477-1487. PubMed ID: 29122151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atopic dermatitis: immunobiology and treatment with immune modulators.
    Leung DY
    Clin Exp Immunol; 1997 Jan; 107 Suppl 1():25-30. PubMed ID: 9020932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10.
    Kaesler S; Volz T; Skabytska Y; Köberle M; Hein U; Chen KM; Guenova E; Wölbing F; Röcken M; Biedermann T
    J Allergy Clin Immunol; 2014 Jul; 134(1):92-9. PubMed ID: 24698321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in atopic dermatitis and psoriasis: genetic background, barrier function, and therapeutic targets.
    Miyagaki T; Sugaya M
    J Dermatol Sci; 2015 May; 78(2):89-94. PubMed ID: 25771165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts.
    Guttman-Yassky E; Nograles KE; Krueger JG
    J Allergy Clin Immunol; 2011 Jun; 127(6):1420-32. PubMed ID: 21419481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach.
    Di Lernia V
    Expert Opin Ther Targets; 2015 Jan; 19(1):87-96. PubMed ID: 25283256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multipolarity of cytokine axes in the pathogenesis of atopic dermatitis in terms of age, race, species, disease stage and biomarkers.
    Nomura T; Honda T; Kabashima K
    Int Immunol; 2018 Aug; 30(9):419-428. PubMed ID: 29518197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation and itch.
    Werfel T; Biedermann T
    Curr Opin Allergy Clin Immunol; 2015 Oct; 15(5):446-52. PubMed ID: 26308331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab for Moderate-to-Severe Atopic Dermatitis.
    Vangipuram R; Tyring SK
    Skin Therapy Lett; 2017 Nov; 22(6):1-4. PubMed ID: 29091379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune mechanisms leading to atopic dermatitis.
    Novak N; Bieber T; Leung DY
    J Allergy Clin Immunol; 2003 Dec; 112(6 Suppl):S128-39. PubMed ID: 14657843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights.
    Jung T; Stingl G
    J Allergy Clin Immunol; 2008 Dec; 122(6):1074-81. PubMed ID: 18992925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.